ADAPTIVE BIOTECHNOLOGIES CORPORATION Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 24.30 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 24.30M shares, a 15.63% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 25.70M shares, a 4.46% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 5.90M shares, a 78.07% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 28.80M shares, a 2.85% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 27.80M shares, a 3.73% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 26.80M shares, a 6.77% increase from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 25.10M shares, a 31.40% increase from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 19.10M shares, a 38.43% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 24.30M shares 10-Q · filed 2026-08-04 | 25.00M shares 10-Q · filed 2026-08-04 | ||||||
| 2026-03-31 | 25.70M shares 10-Q · filed 2026-05-05 | |||||||
| 2025-12-31 | 27.80M shares 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | 5.90M shares 10-Q · filed 2025-11-05 | 28.00M shares 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | 28.80M shares 10-Q · filed 2026-08-04 | 28.83M shares 10-Q · filed 2025-08-05 | 27.90M shares 10-Q · filed 2026-08-04 | 27.87M shares 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | 26.90M shares 10-Q · filed 2026-05-05 | 26.90M shares 10-Q · filed 2025-05-01 | ||||||
| 2024-12-31 | 26.80M shares 10-K · filed 2026-02-26 | 26.83M shares 10-K · filed 2025-03-03 | ||||||
| 2024-09-30 | 26.90M shares 10-Q · filed 2025-11-05 | 26.93M shares 10-Q · filed 2024-11-07 | 27.00M shares 10-Q · filed 2025-11-05 | 26.97M shares 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | 28.00M shares 10-Q · filed 2025-08-05 | 26.99M shares 10-Q · filed 2025-08-05 | ||||||
| 2024-03-31 | 25.97M shares 10-Q · filed 2025-05-01 | |||||||
| 2023-12-31 | 25.10M shares 10-K · filed 2026-02-26 | 25.13M shares 10-K · filed 2024-02-29 | ||||||
| 2023-09-30 | 26.02M shares 10-Q · filed 2024-11-07 | 25.21M shares 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 27.48M shares 10-Q · filed 2024-08-01 | 24.55M shares 10-Q · filed 2024-08-01 | ||||||
| 2023-03-31 | 22.09M shares 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | 19.10M shares 10-K · filed 2025-03-03 | |||||||
| 2022-09-30 | 19.98M shares 10-Q · filed 2023-11-09 | 18.86M shares 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | 20.55M shares 10-Q · filed 2023-08-02 | 18.29M shares 10-Q · filed 2023-08-02 | ||||||
| 2022-03-31 | 16.00M shares 10-Q · filed 2023-05-03 | |||||||
| 2021-12-31 | 13.80M shares 10-K · filed 2024-02-29 | |||||||
| 2021-09-30 | 13.70M shares 10-Q · filed 2022-11-03 | 13.79M shares 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | 13.88M shares 10-Q · filed 2022-08-03 | 13.84M shares 10-Q · filed 2022-08-03 | ||||||
| 2021-03-31 | 13.79M shares 10-Q · filed 2022-05-04 | |||||||
| 2020-12-31 | 16.22M shares 10-K · filed 2023-02-14 | |||||||
| 2020-09-30 | 15.83M shares 10-Q · filed 2021-11-03 | 16.58M shares 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | 17.02M shares 10-Q · filed 2021-08-04 | 16.95M shares 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | 16.88M shares 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | 63.38M shares 10-K · filed 2022-02-15 | |||||||
| 2019-09-30 | 17.53M shares 10-Q · filed 2020-11-10 | 78.83M shares 10-Q · filed 2020-11-10 | ||||||
| 2019-06-30 | 110.76M shares 10-Q · filed 2020-08-10 | 109.99M shares 10-Q · filed 2020-08-10 | ||||||
| 2019-03-31 | 109.28M shares 10-Q · filed 2020-05-12 | |||||||
| 2018-12-31 | 107.60M shares 10-K · filed 2021-02-24 | |||||||
| 2018-09-30 | 107.70M shares 10-Q · filed 2019-11-12 | 107.37M shares 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | 107.84M shares 10-Q · filed 2019-08-13 | 107.19M shares 10-Q · filed 2019-08-13 | ||||||
| 2017-12-31 | 101.23M shares 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |